Summary by Moomoo AI
On July 5th, 2024, CSPC Pharma announced that its developed Rosartan capsules (20mg/50mg) have been granted a drug registration certificate by China National Medical Products Administration, becoming China's first generic low oxygen inducible factor inhibitor to be approved. This medication is used for the treatment of anemia caused by chronic kidney disease, improving the absorption and utilization of iron by patients and correcting anemia. The approval will enrich the Group's product line in the field of blood and hematopoietic system treatment, providing new treatment options for patients. The board of directors led by Chairman Cai Dongchen of CSPC Pharma expressed their satisfaction with this.